Close
Digital Health & Ai Innovation summit 2026
APE 2026

Patent granted for tech used in cuff-based blood pressure devices

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Natera Adds ctDNA-Based MRD Tests with...

In an all-stock transaction, Natera, which is the cell-free...

FDA Launches Technology-Enabled Meaningful Patient Outcomes

Technology-Enabled Meaningful Patient Outcomes – TEMPO has been launched...

US Healthcare Providers to Benefit from...

The federal government has formally withdrawn the Biden-era minimum...

CardieX Limited has announced that its subsidiary ATCOR was granted a new patent by the European Patent Office (EPO) for the company’s SphygmoCor technology used in cuff-based blood pressure devices.

EPO Patent Number EP2566387 further protects the company’s intellectual property in relation to the measurement of a central blood pressure (BP) waveform with cardiovascular features using a brachial cuff. Patent EP2566387 specifically covers non-invasively estimating the heart’s pressure and pressure waveform related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure. The patent provides a simple tool to clinically diagnose and estimate the risk of heart disease.

Examining officers from the EPO referenced the substantial differences to existing patents when granting the new patent to ATCOR, demonstrating the unique nature of the technology. The granting of the European patent follows similar patents granted in the United States and Japan with the new European patent in force until 2034.

ATCOR currently sells the XCEL central blood pressure device and has a partnership with SunTech Medical for the Oscar 2 ABPM device, which both incorporate ATCOR’s SphygmoCor and brachial cuff technology. The company also recently announced a partnership with Andon for the development

of a home-based BP device with advanced cardiovascular vital signs features.

Latest stories

Related stories

Natera Adds ctDNA-Based MRD Tests with Acquisition of Foresight Diagnostics

In an all-stock transaction, Natera, which is the cell-free...

FDA Launches Technology-Enabled Meaningful Patient Outcomes

Technology-Enabled Meaningful Patient Outcomes – TEMPO has been launched...

US Healthcare Providers to Benefit from Minimum Nurse Staffing Rule Repeal

The federal government has formally withdrawn the Biden-era minimum...

Purehealth, Dorchester Partner to Bring Luxury Hospitality in Healthcare

PureHealth has gone on to announce a first-of-its-kind partnership...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »